Yes, an SGLT2 inhibitor is strongly recommended for this patient.
This 76-year-old man with type 2 diabetes and ischemic cardiomyopathy with an EF of 50% should be started on an SGLT2 inhibitor, specifically either dapagliflozin 10 mg daily or empagliflozin 10 mg daily. 1
Rationale Based on Current Guidelines
The most recent 2025 Canadian Cardiovascular Society/Canadian Heart Failure Society guidelines explicitly recommend SGLT2 inhibitors as evidence-based, first-tier therapy for heart failure with nonreduced ejection fraction (HFnrEF, defined as LVEF >40%), which includes this patient's EF of 50% 1. The 2022 AHA/ACC/HFSA guidelines similarly established SGLT2 inhibitors as foundational therapy across the heart failure spectrum 2.
Key Evidence Supporting This Recommendation
Cardiovascular Benefits Regardless of Diabetes Status
- The DELIVER trial specifically studied patients with HFnrEF (like this patient) and demonstrated that dapagliflozin reduced the composite outcome of heart failure hospitalization, urgent HF visits, or cardiovascular death by 18% (16.4% vs 19.5%, HR 0.82) 1
- Critically, the treatment benefit showed no heterogeneity based on diabetes status, LVEF, or sex 1
- The EMPEROR-PRESERVED trial with empagliflozin showed similar benefits, reducing cardiovascular death or heart failure hospitalization by 21% (HR 0.79) 1
Dual Benefit for Diabetes and Heart Disease
This patient has the ideal profile for SGLT2 inhibitor therapy because he has both type 2 diabetes and ischemic cardiomyopathy:
- Early trials in patients with type 2 diabetes and cardiovascular disease demonstrated 31% reduction in heart failure hospitalizations, independent of glucose-lowering effects 2
- Subsequent trials confirmed benefits extend across the full LVEF spectrum, including preserved ejection fraction 1
Mortality and Morbidity Outcomes
- Meta-analysis of 7 RCTs including 13,454 participants with HFnrEF showed SGLT2 inhibitors significantly reduce heart failure hospitalizations by 21% (HR 0.79) 1
- Real-world data shows 87% reduction in heart failure hospitalization risk in patients with HFpEF and type 2 diabetes (HR 0.13) 3
- Benefits observed for both reduced EF (HR 0.61) and preserved EF (HR 0.55) populations 4
Practical Implementation
Starting Regimen
- Dapagliflozin 10 mg once daily (no titration needed) OR
- Empagliflozin 10 mg once daily (can increase to 25 mg if tolerated) 1
Key Contraindications to Check
- eGFR <20-30 mL/min/1.73 m² (depending on agent) 2
- Systolic blood pressure <95-100 mm Hg 2
- Type 1 diabetes 2
- Active diabetic ketoacidosis
Monitoring Considerations
- Volume status (risk of dehydration, especially with concurrent diuretics)
- Genital mycotic infections (manageable, low risk)
- Ketoacidosis risk (very low in type 2 diabetes, but counsel on sick-day management)
- Renal function (SGLT2 inhibitors actually slow eGFR decline long-term) 2
Common Pitfalls to Avoid
- Don't withhold based on "adequate" diabetes control - The cardiovascular benefits are independent of glucose-lowering effects 2
- Don't wait for heart failure symptoms to worsen - Early initiation prevents progression and hospitalizations 1
- Don't be deterred by age - Recent data from very old adults (median age 88.6 years) shows 82.3% prescription rates with good safety profiles 5
- Don't assume benefits are limited to reduced EF - Evidence clearly demonstrates benefit across the entire LVEF spectrum, including EF 50-60% and >60% 1, 6
Additional Cardiovascular Protection
Beyond heart failure benefits, SGLT2 inhibitors provide:
- Renal protection with slower eGFR decline 2, 1
- Reduced stroke risk (OR 0.67) in post-MI populations 7
- Anti-inflammatory and antifibrotic effects contributing to reverse cardiac remodeling 1
- Improved quality of life (KCCQ score improvements) 6
The evidence is unequivocal: this patient should be started on an SGLT2 inhibitor immediately as part of guideline-directed medical therapy for both his diabetes and ischemic cardiomyopathy.